LymphedemaV1, PubMed, Curation, bibRecord, 000452

Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema.

Identifieur interne : 000452 ( PubMed/Curation ); précédent : 000451; suivant : 000453

Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema.

Auteurs : Wen Zhu [République populaire de Chine] ; Dan Li ; Xiaoqin Li ; Jin Ren ; Wenqi Chen ; Hangang Gu ; Yongqian Shu ; Deqiang Wang

Source :

Anti-cancer drugs [ 1473-5741 ] ; 2017.

RBID : pubmed:27997437

Abstract

Docetaxel-based chemotherapy can lead to fluid retention and secondary peripheral edema of the extremities, but its association with lymphedema remains unclear. In this study, we retrospectively investigated the relationship between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema. Patients with stage II/III breast cancer who received adjuvant chemotherapy were evaluated for lymphedema on the basis of arm circumference measurements. The incidence and risk factors of lymphedema were determined by Kaplan-Meier and Cox proportional hazard analyses. A total of 320 patients were included. Specifically, 182 patients received docetaxel and 138 patients did not receive docetaxel. Compared with docetaxel-free chemotherapy, docetaxel-based chemotherapy significantly increased the 2.5-year cumulative incidence of all-grade lymphedema (19.91 vs. 32.09%; P=0.011), which was further verified in grade 1-2 (P=0.012), but not in grade 3 lymphedema (P=0.448). Similar results were found in a comparison between docetaxel and nontaxane, but not in a comparison between docetaxel and other taxanes. Multivariate analysis showed that docetaxel-based chemotherapy is an independent risk factor for both all-grade (hazard ratio=1.73; P=0.017) and grade 1-2 lymphedema (hazard ratio=1.87; P=0.022). In conclusion, adjuvant docetaxel-based chemotherapy significantly increased the risk of breast cancer-related lymphedema.

DOI: 10.1097/CAD.0000000000000468
PubMed: 27997437

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000452

Links to Exploration step

pubmed:27997437

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema.</title>
<author><name sortKey="Zhu, Wen" sort="Zhu, Wen" uniqKey="Zhu W" first="Wen" last="Zhu">Wen Zhu</name>
<affiliation wicri:level="1"><nlm:affiliation>aDepartment of Medical Oncology, The Cancer Therapy Center, Affiliated Hospital of Jiangsu University, Zhenjiang bDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>aDepartment of Medical Oncology, The Cancer Therapy Center, Affiliated Hospital of Jiangsu University, Zhenjiang bDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Li, Dan" sort="Li, Dan" uniqKey="Li D" first="Dan" last="Li">Dan Li</name>
</author>
<author><name sortKey="Li, Xiaoqin" sort="Li, Xiaoqin" uniqKey="Li X" first="Xiaoqin" last="Li">Xiaoqin Li</name>
</author>
<author><name sortKey="Ren, Jin" sort="Ren, Jin" uniqKey="Ren J" first="Jin" last="Ren">Jin Ren</name>
</author>
<author><name sortKey="Chen, Wenqi" sort="Chen, Wenqi" uniqKey="Chen W" first="Wenqi" last="Chen">Wenqi Chen</name>
</author>
<author><name sortKey="Gu, Hangang" sort="Gu, Hangang" uniqKey="Gu H" first="Hangang" last="Gu">Hangang Gu</name>
</author>
<author><name sortKey="Shu, Yongqian" sort="Shu, Yongqian" uniqKey="Shu Y" first="Yongqian" last="Shu">Yongqian Shu</name>
</author>
<author><name sortKey="Wang, Deqiang" sort="Wang, Deqiang" uniqKey="Wang D" first="Deqiang" last="Wang">Deqiang Wang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:27997437</idno>
<idno type="pmid">27997437</idno>
<idno type="doi">10.1097/CAD.0000000000000468</idno>
<idno type="wicri:Area/PubMed/Corpus">000452</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000452</idno>
<idno type="wicri:Area/PubMed/Curation">000452</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000452</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema.</title>
<author><name sortKey="Zhu, Wen" sort="Zhu, Wen" uniqKey="Zhu W" first="Wen" last="Zhu">Wen Zhu</name>
<affiliation wicri:level="1"><nlm:affiliation>aDepartment of Medical Oncology, The Cancer Therapy Center, Affiliated Hospital of Jiangsu University, Zhenjiang bDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>aDepartment of Medical Oncology, The Cancer Therapy Center, Affiliated Hospital of Jiangsu University, Zhenjiang bDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Li, Dan" sort="Li, Dan" uniqKey="Li D" first="Dan" last="Li">Dan Li</name>
</author>
<author><name sortKey="Li, Xiaoqin" sort="Li, Xiaoqin" uniqKey="Li X" first="Xiaoqin" last="Li">Xiaoqin Li</name>
</author>
<author><name sortKey="Ren, Jin" sort="Ren, Jin" uniqKey="Ren J" first="Jin" last="Ren">Jin Ren</name>
</author>
<author><name sortKey="Chen, Wenqi" sort="Chen, Wenqi" uniqKey="Chen W" first="Wenqi" last="Chen">Wenqi Chen</name>
</author>
<author><name sortKey="Gu, Hangang" sort="Gu, Hangang" uniqKey="Gu H" first="Hangang" last="Gu">Hangang Gu</name>
</author>
<author><name sortKey="Shu, Yongqian" sort="Shu, Yongqian" uniqKey="Shu Y" first="Yongqian" last="Shu">Yongqian Shu</name>
</author>
<author><name sortKey="Wang, Deqiang" sort="Wang, Deqiang" uniqKey="Wang D" first="Deqiang" last="Wang">Deqiang Wang</name>
</author>
</analytic>
<series><title level="j">Anti-cancer drugs</title>
<idno type="eISSN">1473-5741</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Docetaxel-based chemotherapy can lead to fluid retention and secondary peripheral edema of the extremities, but its association with lymphedema remains unclear. In this study, we retrospectively investigated the relationship between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema. Patients with stage II/III breast cancer who received adjuvant chemotherapy were evaluated for lymphedema on the basis of arm circumference measurements. The incidence and risk factors of lymphedema were determined by Kaplan-Meier and Cox proportional hazard analyses. A total of 320 patients were included. Specifically, 182 patients received docetaxel and 138 patients did not receive docetaxel. Compared with docetaxel-free chemotherapy, docetaxel-based chemotherapy significantly increased the 2.5-year cumulative incidence of all-grade lymphedema (19.91 vs. 32.09%; P=0.011), which was further verified in grade 1-2 (P=0.012), but not in grade 3 lymphedema (P=0.448). Similar results were found in a comparison between docetaxel and nontaxane, but not in a comparison between docetaxel and other taxanes. Multivariate analysis showed that docetaxel-based chemotherapy is an independent risk factor for both all-grade (hazard ratio=1.73; P=0.017) and grade 1-2 lymphedema (hazard ratio=1.87; P=0.022). In conclusion, adjuvant docetaxel-based chemotherapy significantly increased the risk of breast cancer-related lymphedema.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27997437</PMID>
<DateCreated><Year>2016</Year>
<Month>12</Month>
<Day>20</Day>
</DateCreated>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5741</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>28</Volume>
<Issue>3</Issue>
<PubDate><Year>2017</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Anti-cancer drugs</Title>
<ISOAbbreviation>Anticancer Drugs</ISOAbbreviation>
</Journal>
<ArticleTitle>Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema.</ArticleTitle>
<Pagination><MedlinePgn>350-355</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/CAD.0000000000000468</ELocationID>
<Abstract><AbstractText>Docetaxel-based chemotherapy can lead to fluid retention and secondary peripheral edema of the extremities, but its association with lymphedema remains unclear. In this study, we retrospectively investigated the relationship between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema. Patients with stage II/III breast cancer who received adjuvant chemotherapy were evaluated for lymphedema on the basis of arm circumference measurements. The incidence and risk factors of lymphedema were determined by Kaplan-Meier and Cox proportional hazard analyses. A total of 320 patients were included. Specifically, 182 patients received docetaxel and 138 patients did not receive docetaxel. Compared with docetaxel-free chemotherapy, docetaxel-based chemotherapy significantly increased the 2.5-year cumulative incidence of all-grade lymphedema (19.91 vs. 32.09%; P=0.011), which was further verified in grade 1-2 (P=0.012), but not in grade 3 lymphedema (P=0.448). Similar results were found in a comparison between docetaxel and nontaxane, but not in a comparison between docetaxel and other taxanes. Multivariate analysis showed that docetaxel-based chemotherapy is an independent risk factor for both all-grade (hazard ratio=1.73; P=0.017) and grade 1-2 lymphedema (hazard ratio=1.87; P=0.022). In conclusion, adjuvant docetaxel-based chemotherapy significantly increased the risk of breast cancer-related lymphedema.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName>
<ForeName>Wen</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>aDepartment of Medical Oncology, The Cancer Therapy Center, Affiliated Hospital of Jiangsu University, Zhenjiang bDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Xiaoqin</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ren</LastName>
<ForeName>Jin</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Wenqi</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gu</LastName>
<ForeName>Hangang</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Shu</LastName>
<ForeName>Yongqian</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Deqiang</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Anticancer Drugs</MedlineTA>
<NlmUniqueID>9100823</NlmUniqueID>
<ISSNLinking>0959-4973</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>12</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>12</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>12</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27997437</ArticleId>
<ArticleId IdType="doi">10.1097/CAD.0000000000000468</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000452 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000452 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:27997437
   |texte=   Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:27997437" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema.

Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki